|
|
Vaccine Detail
|
KRAS-targeted mRNA vaccine |
| Vaccine Information |
- Vaccine Name: KRAS-targeted mRNA vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: mRNA
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: mutated KRAS (G12C, G12D, or G12V) (NCIT_C162186; NCT05202561)
- Immunization Route: Intramuscular injection (i.m.)
- Description: The RNA vaccine injection can be used alone or in combination with PD-1 inhibitor in patients with advanced solid tumors with KRAS mutation (G12C, G12D, or G12V) and HLA type HLA-A11:01 or HLA C08:02. (NCT05202561) The vaccine is a lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets the most commonly occurring KRAS mutations (G12D, G12V, and G12C). The mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. (NCIT_C162186)
|
| Host Response |
|
|
| References |
NCIT_C162186: mRNA-derived KRAS-targeted Vaccine V941 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162186]
NCT05202561: A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors [https://clinicaltrials.gov/study/NCT05202561]
|
|
